

# CITATION REPORT

List of articles citing

Long-term pulmonary hemodynamic effects of  
ambrisentan in pulmonary arterial hypertension

DOI: 10.1016/j.amjcard.2011.03.037  
American Journal of Cardiology, 2011, 108, 302-7.

**Source:** <https://exaly.com/paper-pdf/51169367/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
42	An update on the use of ambrisentan in pulmonary arterial hypertension. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2012</b> , 6, 331-43	4.9	11
41	Safety and efficacy evaluation of ambrisentan in pulmonary hypertension. <i>Expert Opinion on Drug Safety</i> , <b>2012</b> , 11, 1003-11	4.1	16
40	Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension. <i>Current Medical Research and Opinion</i> , <b>2012</b> , 28, 1069-76	2.5	7
39	WHO Group 1 pulmonary arterial hypertension: current and investigative therapies. <i>Progress in Cardiovascular Diseases</i> , <b>2012</b> , 55, 89-103	8.5	18
38	Value of tissue Doppler echocardiography in children with pulmonary hypertension. <i>Journal of the American Society of Echocardiography</i> , <b>2012</b> , 25, 504-10	5.8	43
37	Cardiac Diseases. <b>2012</b> , 28-74		1
36	Glycemic improvement normalizes myocardial microvascular reserve in type 2 diabetes. <i>International Journal of Cardiology</i> , <b>2012</b> , 156, 245-7	3.2	6
35	Ambrisentan for pulmonary arterial hypertension: long term effects on clinical status, exercise capacity and haemodynamics. <i>International Journal of Cardiology</i> , <b>2012</b> , 156, 244-5	3.2	7
34	Treatment of pulmonary hypertension. <i>Medical Science Monitor</i> , <b>2012</b> , 18, RA31-9	3.2	10
33	Rapid determination of ambrisentan enantiomers by enantioselective liquid chromatography using cellulose-based chiral stationary phase in reverse phase mode. <i>Journal of Separation Science</i> , <b>2012</b> , 35, 798-803	3.4	14
32	Pulmonary arterial hypertension. <i>Orphanet Journal of Rare Diseases</i> , <b>2013</b> , 8, 97	4.2	168
31	Management of pulmonary arterial hypertension. <i>Current Opinion in Critical Care</i> , <b>2013</b> , 19, 44-50	3.5	7
30	Current world literature. <i>Current Opinion in Critical Care</i> , <b>2013</b> , 19, 65-73	3.5	
29	Current challenges in pediatric pulmonary hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2013</b> , 34, 627-44	3.9	18
28	Ambrisentan therapy in pulmonary hypertension: clinical use and tolerability in a referral centre. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2014</b> , 8, 71-77	4.9	11
27	Stability-Indicating RP-HPLC Method for the Determination of Ambrisentan and Tadalafil in Pharmaceutical Dosage Form. <i>Scientia Pharmaceutica</i> , <b>2014</b> , 82, 749-63	4.3	13
26	Take a deep breath: understanding pulmonary arterial hypertension. <i>Critical Care Nursing Quarterly</i> , <b>2014</b> , 37, 188-98	2	

25	Drug treatment of pulmonary hypertension in children. <i>Paediatric Drugs</i> , <b>2014</b> , 16, 43-65	4.2	32
24	[Endothelin: From discovery to pharmacotherapeutic innovations]. <i>Presse Medicale</i> , <b>2014</b> , 43, 742-55	2.2	0
23	Current and advancing treatments for pulmonary arterial hypertension in childhood. <i>Expert Review of Respiratory Medicine</i> , <b>2014</b> , 8, 615-28	3.8	2
22	LC-MS/MS characterization of forced degradation products of ambrisentan: development and validation of a stability-indicating RP-HPLC method. <i>New Journal of Chemistry</i> , <b>2014</b> , 38, 3050	3.6	19
21	Ambrisentan: a guide to its use in pulmonary arterial hypertension in the EU. <i>Drugs and Therapy Perspectives</i> , <b>2014</b> , 30, 231-240	1.5	
20	Ambrisentan May Improve Exercise Tolerance and Cardiac Function in Patients With Pulmonary Hypertension. <i>Clinical Therapeutics</i> , <b>2015</b> , 37, 1270-9	3.5	1
19	Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review. <i>Current Medical Research and Opinion</i> , <b>2015</b> , 31, 1793-807	2.5	12
18	Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension. <i>American Journal of Cardiovascular Drugs</i> , <b>2015</b> , 15, 13-26	4	19
17	Ambrisentan in pulmonary arterial hypertension: a guide to its use in the EU. <i>Drugs and Therapy Perspectives</i> , <b>2016</b> , 32, 50-59	1.5	
16	Endothelin Receptor Antagonist. <b>2017</b> , 153-169		
15	Ambrisentan: a review of its use in pulmonary arterial hypertension. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2017</b> , 11, 233-244	4.9	12
14	Diagnosis and Treatment of Pulmonary Hypertension. <b>2017</b> ,		0
13	Ambrisentan?. <b>2017</b> ,		
12	[Declaration of the Chilean Academy of Medicine of Law 20.850 "On clinical trials of pharmaceutical products and medical devices" and of the bylaw that will regulate its application]. <i>Revista Medica De Chile</i> , <b>2017</b> , 145, 380-385	0.5	2
11	[Declaration of the Chilean Academy of Medicine of Law 20.850 "On clinical trials of pharmaceutical products and medical devices" and of the bylaw that will regulate its application]. <i>Revista Chilena De Infectologia</i> , <b>2017</b> , 34, 151-155	0	
10	Ambrisentan □ tadalafil in WHO functional class II/III pulmonary arterial hypertension: a guide to its use in the EU. <i>Drugs and Therapy Perspectives</i> , <b>2018</b> , 34, 289-299	1.5	
9	Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study). <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 217	5.7	20
8	Heritable and Idiopathic Forms of Pulmonary Arterial Hypertension. <b>2020</b> , 439-462		0

7	The importance of right ventricular evaluation in risk assessment and therapeutic strategies: Raising the bar in pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , <b>2020</b> , 301, 183-189 <sup>3,2</sup>	22
6	Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis. <i>Scientific Reports</i> , <b>2020</b> , 10, 15931	4.9 5
5	Drug Treatment of Pulmonary Hypertension in Children. <i>Paediatric Drugs</i> , <b>2020</b> , 22, 123-147	4.2 7
4	"Treat and repair" strategy for shunt lesions: a critical review. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894020917885	
3	Rapid determination of ambrisentan enantiomers by enantioselective liquid chromatography using cellulose-based chiral stationary phase in reverse phase mode. <i>Journal of Separation Science</i> , <b>2012</b> , n/a-n/a <sup>3,4</sup>	
2	DEVELOPMENT AND VALIDATION OF RP-HPLC-PDA METHOD FOR THE ESTIMATION OF AMBRISENTAN IN BULK AND TABLET DOSAGE FORMS. <i>Indian Drugs</i> , <b>2016</b> , 53, 43-47	0.2 1
1	Extractive spectrophotometric determination of ambrisentan. <i>Advanced Pharmaceutical Bulletin</i> , <b>2013</b> , 3, 231-7	4.5 5